Related Experiment Video
Updated: Mar 24, 2026

Glycan Node Analysis: A Bottom-up Approach to Glycomics
Published on: May 22, 2016
Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives
Joanne Chia1, Germaine Goh1, Frederic Bard2
1Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, 138673, Singapore.
Background:
While the underlying causes of cancer are genetic modifications, changes in cellular states mediate cancer development. Tumor cells display markedly changed glycosylation states, of which the O-GalNAc glycans called the Tn and TF antigens are particularly common. How these antigens get over-expressed is not clear. The expression levels of glycosylation enzymes fail to explain it.
Scope Of Review:
We describe the regulation of O-GalNAc glycosylation initiation and extension with emphasis on the initiating enzymes ppGalNAcTs (GALNTs), and introduce the GALA pathway--a change in GALNTs compartmentation within the secretory pathway that regulates Tn levels. We discuss the roles of O-GalNAc glycans and GALNTs in tumorigenic processes and finally consider diagnostic and therapeutic perspectives.
Major Conclusions:
Contrary to a common hypothesis, short O-glycans in tumors are not the result of an incomplete glycosylation process but rather reveal the activation of regulatory pathways. Surprisingly, high Tn levels reveal a major shift in the O-glycoproteome rather than a shortening of O-glycans. These changes are driven by membrane trafficking events.
General Significance:
Many attempts to use O-glycans for biomarker, antibody and therapeutic vaccine development have been made, but suffer limitations including poor sensitivity and/or specificity that may in part derive from lack of a mechanistic understanding. Deciphering how short O-GalNAc glycans are regulated would open new perspectives to exploit this biology for therapeutic usage. This article is part of a Special Issue entitled "Glycans in personalised medicine" Guest Editor: Professor Gordan Lauc.
Insights
Cancer cells exhibit altered O-GalNAc glycans (Tn and TF antigens), not due to incomplete processes but activated regulatory pathways. Understanding this regulation, particularly the GALA pathway, is key for cancer diagnostics and therapeutics.
Area of Science:
- Biochemistry
- Cancer Biology
- Glycobiology
Background:
- Cancer development involves genetic modifications and altered cellular states, notably changes in glycosylation.
- Tumor cells frequently over-express O-GalNAc glycans, specifically Tn and TF antigens, though the mechanisms remain unclear.
- Simple explanations like altered glycosylation enzyme levels do not fully account for the observed antigen overexpression.
Purpose of the Study:
- To elucidate the regulatory mechanisms of O-GalNAc glycosylation initiation and extension.
- To introduce the GALA pathway, a novel concept involving enzyme compartmentation in regulating Tn antigen levels.
- To discuss the implications of O-GalNAc glycans and their regulatory enzymes (GALNTs) in cancer and explore diagnostic/therapeutic potential.
Main Methods:
- Focus on the initiating enzymes of O-GalNAc glycosylation, polypeptide N-acetylgalactosaminyltransferases (ppGalNAcTs or GALNTs).
- Description of the GALA pathway, detailing changes in GALNTs compartmentation within the secretory pathway.
- Analysis of the roles of O-GalNAc glycans and GALNTs in tumorigenic processes.
Main Results:
- Contrary to previous hypotheses, elevated short O-glycans in tumors indicate activated regulatory pathways, not incomplete glycosylation.
- High Tn antigen levels signify a substantial shift in the O-glycoproteome, rather than a mere shortening of glycans.
- These significant glycan alterations are driven by underlying membrane trafficking events.
Conclusions:
- The study challenges the notion of incomplete glycosylation as the cause of short O-glycans in tumors.
- Activation of specific regulatory pathways, including the GALA pathway, is responsible for altered O-glycan expression.
- A deeper mechanistic understanding of O-GalNAc glycan regulation is crucial for developing effective biomarkers, antibodies, and therapeutic vaccines for cancer.
More Related Videos
10:59Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments
Published on: February 7, 2025
13:36Author Spotlight: Dendritic Cells Maturation Using Sialidases-Based Enzymatic Treatment of the Cell Surface
Published on: October 20, 2023
Related Concept Videos
Proteoglycans
Protein Glycosylation
Glycosylation occurs in...
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Glycocalyx and its Functions